Last updated: March 21, 2026
What is NDC 42806-0757?
NDC 42806-0757 refers to a specific drug identified in the National Drug Code database. Based on available data, this NDC corresponds to [drug name], used primarily for [indication]. The drug's composition, formulation, and route of administration impact its market potential and pricing.
Market Size and Usage Data
US Market Overview
- Estimated annual prescriptions: [approximate number based on recent data]
- Market penetration: [market share compared to competitors]
- Patient population: [demographics, age groups]
Growth Drivers
- Rising prevalence of [target condition]
- Approval of new indications or expanded label
- Favorable insurance reimbursement policies
Competitive Landscape
| Competitor |
Market Share |
Price per unit |
Key Differentiator |
| [Competitor 1] |
X% |
$XX |
[Feature/Benefit] |
| [Competitor 2] |
Y% |
$YY |
[Feature/Benefit] |
| [This Drug] |
Z% |
$ZZ |
[Unique trait] |
Regulatory Context
- FDA approval date: [date]
- Label expansions: [details]
- Pending or recent patent status: [details]
Price Projection Data
Historical Pricing
- Launch price: $XX per unit
- Current average wholesale price (AWP): $YY per unit
- Reimbursement trends: Payment adjustments over past three years
Short-Term Forecast (Next 1-2 Years)
- Typical first-year price increases for newly launched drugs in this class: 3-5%
- Projected average wholesale price range: $XX - $YY per unit
Long-Term Outlook (Next 3-5 Years)
- Price trends often dependent on patent expiry, biosimilar entry, or generics
- Anticipated discounts upon patent expiration: 20-40%
- Impact of market competition reducing prices: Estimated decrease of 10-15% over 3 years after patent loss
Factors Influencing Price Changes
- New indications can justify higher prices
- Changes in insurance reimbursement policies
- Entry of biosimilars or generics reduces prices
Key Market Dynamics
- Patent protection: [expiration date]
- Biosimilar/generic threat: [timing estimates]
- Manufacturer's market strategies: Price positioning, rebates, and formulary placement
- Potential for drug rebates or discounts affecting net prices
Strategic Considerations for Stakeholders
- R&D investments should evaluate potential for label expansion
- Investors should track patent timelines and biosimilar pathways
- Payers and providers should monitor reimbursement policies affecting net prices
Key Takeaways
- The drug in question occupies a competitive market, with recent growth driven by increased prevalence and new indications.
- Current pricing averages between $XX and $YY per unit, with expected modest increases over the next two years.
- Price declines are likely after patent expiry, with discounts of up to 40% anticipated for biosimilars or generics.
- Market share and pricing are influenced by regulatory decisions, biosimilar entry, and payer policies.
FAQs
1. What factors influence the price of the drug?
Reimbursement policies, patent status, competition, and clinical value influence this drug’s price.
2. When is patent expiration expected?
Patents are expected to expire in [year], opening opportunities for biosimilar competition.
3. Are biosimilars or generics available?
Pending or upcoming entries are probable following patent expiration, which could significantly reduce prices.
4. How does market share impact pricing?
Higher market share allows for premium pricing, while increased competition drives prices down.
5. What future trends could affect the market?
Label expansions, biosimilar approvals, and payer negotiations are critical factors shaping future dynamics.
References
- U.S. Food and Drug Administration. (2022). [Approval and label information for the drug].
- IQVIA. (2023). National Prescription Audit Data.
- Centers for Medicare & Medicaid Services. (2023). Reimbursement trends report.
- Patents and Exclusivities. (2023). [Patent status overview].
- Market Data Reports. (2023). Competitive landscape analysis.
[Note: Specific data, such as actual prescription volumes, prices, or patent dates, should be retrieved from current databases and regulatory filings to ensure accuracy.]
